Drug General Information (ID: DDIDL67PQK)
Drug Name			Cisplatin		Drug Info		Plazomicin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Aminoglycosides//Antibiotics
Structure

Mechanism of Cisplatin-Plazomicin Interaction (Severity Level: Moderate)
Increased risk of hypomagnesemia Click to Show/Hide Mechanism Graph
Drug Name		Cisplatin				Plazomicin
Mechanism		Hypomagnesemia				Hypomagnesemia
Key Mechanism Factor 1
		Factor Name		Hypomagnesemia
		Factor Description		Hypomagnesemia is a condition that occurs when you have too much magnesium in your body. Symptoms of hypomagnesemia include: nausea, vomiting, neurological damage, abnormally low blood pressure (hypotension), flushing, and headaches.
Mechanism Description		Increased risk of hypomagnesemia by the combination of Cisplatin and Plazomicin

Recommended Action
Management		In patients currently receiving cisplatin therapy, the use of less nephrotoxic antimicrobials is preferable. If cisplatin and an aminoglycoside must be used together, renal function and serum magnesium should be monitored carefully.

References
1	Hass A, Anderson L, Lad T "The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichlorophatinum in cancer patients." J Infect Dis 147 (1983): 363
2	Dentino M, Luft FC, Yum MN, et al "Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man." Cancer 41 (1978): 1274-81
3	Blachley JD, Hill JB "Renal and electrolyte disturbances associated with cisplatin." Ann Intern Med 95 (1981): 628-32